After 40 hours, when you're tired of an arrow in your side...
“Need has nothing to do with it”
The only dots I see are maybe Roswell turning some of financing advantages over to Eastern. These Taplmmune deals look pretty creative. I haven't looked at the other Eastern companies, but need to do that. Swartz may have gone through #$%$ and Fast Eddie to get King. King is definitely Swartz' man.
Good point, Wook. Shorts should be pumping to get that price up. With a long-term downward bias, help is needed on the pump side.
Any of you iCLUB interlopers - while tracking job openings, have you seen any openings for finance types? With all the sources of funding, PP should be staffing a robust Finance Department.
In Phase 1 over 95% of patients in both Her2neu positive breast cancer and in folate receptor alpha positive ovarian cancer demonstrated positive immune responses to TapImmune's antigens. Success in these trials has provided a strong basis for progression to Phase 2. "We plan to initiate a Phase 2 clinical trial in triple negative breast cancer in the near future," said Wilson.
Triple-negative breast cancer ("TNBC") is breast cancer that is unresponsive to standard biomarker-targeted or hormonal treatment. TNBC tumors test negative for the estrogen and progesterone receptors and positive for the HER2 receptor. Approximately 15-20% of all breast cancer patients are triple negative and there are few treatment options for these patients. In the United States approximately 40,000 women are diagnosed with TNBC each year and there are many hundreds of thousands of recovered breast cancer patients at high risk of recurrence. This indication and lack of available therapeutics make this drug an ideal candidate for Fast Track and Orphan Drug designations from the FDA and the company will be making those applications along with its Phase 2 FDA filings.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastases, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatments.
TapImmune Receives $1,000,000 from Strategic Investor
Investment bolsters immediate capital needs for progressing clinical programs
March 10, 2015 8:30 AM
SEATTLE, March 10, 2015 /PRNewswire/ -- TapImmune, Inc. (TPIV), is pleased to announce a US$1 million investment from Eastern Capital Limited under the same terms as the recent January 12, 2015 round of financing.
"We believe immunotherapy is one of the most exciting new approaches to the treatment of multiple cancers and promising early clinical results suggest TapImmune's immunotherapies could become leading T-Cell stimulating therapeutics," said Glynn Wilson Ph.D., CEO and Chairman of TapImmune. "Our platform is designed to deliver a cost-effective, injectable therapy that stimulates the proliferation of specifically targeted, activated T-cells leading to a robust immune response supportive of the destruction of both tumor and metastatic cancer cells."
Eastern Capital Limited will receive a standard 5-year warrant that, if exercised, would provide $7.5 million in funding and callable warrants that, under certain market conditions, will provide an additional $7.0 million in capital to TapImmune. Additional warrants, exercisable only to the extent the callable warrants are exercised or called, could provide the Company with a further $10.0 million in funding. H.C. Wainwright & Co. acted as exclusive placement agent for the transaction.
"We are happy to participate in this innovative financing, improving TapImmune's access to capital, possibly for years to come. Cancer Immunotherapy is emerging as a powerhouse of biological intervention and we are impressed with TapImmune's approach and with the clinical progress made to date," said Mark VanDevelde, a Director of Eastern Capital Limited. "We are looking forward to the initiation of Phase 2 trials."
In Phase 1 over 95% of patients in both Her2neu positive breast cancer and in folate receptor alpha positive ovarian can
TapImmune Appoints John N. Bonfiglio, Ph.D., to its Board of Directors
Accomplished Biotech CEO is currently a Strategic Advisor to TapImmune
SEATTLE, July 30, 2015 /PRNewswire/ -- TapImmune Inc. (TPIV) is pleased to announce the appointment of John N. Bonfiglio, Ph.D., MBA to its Board of Directors. Since February, 2015 Dr. Bonfiglio has been a Strategic Advisor to the management team assisting with financing, development, and implementation of an improved Capital Markets and Shareholder IR/PR program.
Dr. Bonfiglio is a highly successful Biotech CEO with broad experience in corporate strategy, financing, market interactions, and business development. Most recently, Dr. Bonfiglio served as President and CEO of Oragenics, where he refocused the company and raised over $29 million dollars in the public markets while positioning the company for a successful re-listing on the New York Stock Exchange (NYSE). Prior to joining Oragenics, he served as President and CEO of Argos Therapeutics, where he raised over $35 million dollars for the Company and led the company in a successful Phase 2 study in renal cell carcinoma. As President and CEO of the Immune Response Corporation, he was responsible for turning the Company around through improved therapeutic focus, capital raising (over $50 million), and improved investor relations resulting in a significant appreciation in stock price and shareholder value. Dr. Bonfiglio also served as President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation's Immunotherapy Division.
Just after the proxy, the conference call & First Quarter Filings. A little more than a month after that is the annual meeting. If the Authorized is increased; there is no word on the first and second look-ins; and the trial is not 100% enrolled, can King continue as CEO? In any event, I think he's going to the fresh new building with the daughter to be an AVID stuffed suit.